source
- Vaderis fuels up with $152M series B to test rare vascular disease in Phase 3Vaderis is hoping that engasertib will become the first approved medicine for hereditary hemorrhagic telangiectasia, a rare condition that can cause spontaneous bleeding.BioSpace · 6h ago↗ source
- Epicrispr raises $90M to rewrite treatment of rare muscle diseaseEpicrispr Biotechnologies has raised $90 million in a series C round backed by investors including Sanofi Ventures, positioning the biotech to advance a pipeline of epigenetic medicines led by an e…Fierce Biotech · 7h ago↗ source
- Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drugSentynl Therapeutics has penned a deal potentially worth $475 million for the option to market Mereo BioPharma's phase 3-ready rare genetic respiratory disease drug in the U.S.